Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart + hypofractionated radiotherapy + GM-CSF then Benmelstobart + anlotinib in PD-1/PD-L1 refractory NSCLC
ChiCTR2500108817Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanjing Medical University
- Start
- Sep 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benmelstobart, anlotinib and sargramostim in non-small cell lung cancer (NSCLC), sponsored by The Second Affiliated Hospital of Nanjing Medical University. Primary endpoint: Objective Response Rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
benmelstobartanlotinibsargramostim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500108817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108817.